

## Special Issue

# Novel Vaccine Stabilization and Delivery Technologies: Edition II

### Message from the Guest Editors

To formulate effective prophylactic or therapeutic vaccines, it is becoming apparent that both the innate and adaptive immune systems must be stimulated to protect from the current and future recognition of the target antigen. Further, vaccine formulation in a delivery system that has high patient acceptability, which stabilizes the vaccine and promotes cost-effective delivery, is essential for long-term use. Vaccine stability can be improved by optimizing the composition of formulations by the addition of excipients, thus, restricting molecular mobility and preventing degradation. This Special Issue focuses on the different platforms that are available for developing robust immunotherapies for use as vaccine candidates, along with vaccine stabilizations such as lyophilization, spray drying, nanoparticles, lipid vesicles, etc., and their subsequent delivery via various routes of administration. We encourage your submission and note that there is a short turnaround time for publication.

### Guest Editors

Prof. Dr. Martin J. D'Souza

Dr. Mohammad N. Uddin

Dr. Rikhav Gala

Dr. Bernadette D'Souza

### Deadline for manuscript submissions

closed (31 December 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/138194](https://mdpi.com/si/138194)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).